Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis

Yang CW., Chen RD., Zhu QR., Han SJ., Kuang MJ.

Meta-analysis with a reported sample of 293 on Chronic Inflammation, Immune Modulation, published in Front Immunol (2022) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Front Immunol (2022)
Reported sample size
293
Source database
Europe PMC
PMID
36105796
PMCID
PMC9467457
DOI
10.3389/fimmu.2022.923286
Citations
5

Abstract (original English)

Objectives A major challenge for COVID-19 therapy is dysregulated immune response associated with the disease. Umbilical cord mesenchymal stromal cells (UC-MSCs) may be a promising candidate for COVID-19 treatment owing to their immunomodulatory and anti-inflammatory functions. Therefore, this study aimed to evaluate the effectiveness of UC-MSCs inpatients with COVID-19. Method Medline, Embase, PubMed, Cochrane Library, and Web of Science databases were searched to collect clinical trials concerning UC-MSCs for the treatment of COVID-19. After literature screening, quality assessment, and data extraction, a systematic review and meta-analysis of the included study were performed. Results This systematic review and meta-analysis were prospectively registered on PROSPERO, and the registration number is CRD42022304061. After screening, 10 studies involving 293 patients with COVID-19 were eventually included . Our meta-analysis results showed that UC-MSCs can reduce mortality (relative risk [RR] =0.60, 95% confidence interval [CI]: [0.38, 0.95], P=0.03) in COVID-19 patients. No significant correlation was observed between adverse events and UC-MSC treatment (RR=0.85, 95% CI: [0.65, 1.10], P=0.22; RR=1.00, 95%CI: [0.64, 1.58], P=1.00) . In addition, treatment with UC-MSCs was found to suppress inflammation and improve pulmonary symptoms. Conclusions UC-MSCs hold promise as a safe an

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Mesenchymal Stem CellsUmbilical CordHumansImmunomodulationCOVID-19COVID-19 Drug Treatment

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research